# EPM2A

## Overview
The EPM2A gene encodes the protein laforin, a dual-specificity phosphatase that plays a pivotal role in glycogen metabolism and cellular homeostasis. Laforin is characterized by its unique structure, which includes a carbohydrate-binding module and a dual-specificity phosphatase domain, allowing it to bind glycogen and remove phosphate groups, thus maintaining glycogen's normal structure and solubility (Worby2006Laforin; Wang2002A). This function is crucial in preventing the formation of Lafora bodies, insoluble polyglucosans associated with Lafora disease, a severe form of progressive myoclonus epilepsy (Roach2012Glycogen; Singh2009Lafora). Beyond its role in glycogen metabolism, laforin also regulates autophagy by modulating the mTOR signaling pathway, thereby contributing to cellular protein degradation and homeostasis (Aguado2010Laforin). Mutations in the EPM2A gene can lead to a loss of laforin's phosphatase activity, resulting in the pathological accumulation of glycogen-like polyglucosans and the clinical manifestations of Lafora disease (Parihar2018Lafora; Singh2009Lafora).

## Structure
The EPM2A gene encodes laforin, a protein characterized by a unique structure that includes a carbohydrate-binding module (CBM) and a dual-specificity phosphatase (DSP) domain. The CBM, located at the NH2-terminus, is crucial for binding to glycogen and is part of the CBM20 family, although it shows low homology with other CBM20 members (Castanheira2011Recombinant; Wang2002A). The DSP domain, located at the COOH-terminus, contains a catalytic motif HCXXGXXR(S/T) (CX5R), which is typical of the Protein Tyrosine Phosphatase (PTP) superfamily (SánchezMartín2013Dimerization; Worby2006Laforin).

Laforin's tertiary structure is supported by alpha-helices and beta-sheets, contributing to its functional conformation. The protein can form dimers, a process influenced by redox conditions and involving cysteine residues, particularly Cys329, which is essential for dimerization (SánchezMartín2013Dimerization; Emanuelle2016Unique). Despite its ability to dimerize, laforin predominantly exists as a monomer with full phosphatase activity (Dukhande2011Laforin). The dimerization is not required for its interaction with malin, an E3 ubiquitin ligase, which regulates laforin through ubiquitination (SánchezMartín2013Dimerization). The structural configuration of laforin allows it to effectively participate in glycogen metabolism, preventing the formation of Lafora bodies associated with Lafora disease (Emanuelle2016Unique).

## Function
The EPM2A gene encodes laforin, a dual-specificity phosphatase that plays a critical role in glycogen metabolism and autophagy in healthy human cells. Laforin functions as a glycogen phosphatase, removing phosphate groups from glycogen to maintain its normal structure and solubility, thereby preventing the formation of insoluble polyglucosans known as Lafora bodies (Roach2012Glycogen; Singh2009Lafora). This activity is crucial for preventing the pathological changes associated with Lafora disease, a form of progressive myoclonus epilepsy (Roach2012Glycogen).

Laforin also regulates autophagy, a cellular process for degrading long-lived proteins and organelles, by modulating the mTOR signaling pathway. In healthy cells, laforin inhibits mTOR, promoting autophagy and ensuring proper protein degradation (Aguado2010Laforin). This regulation is essential for maintaining cellular homeostasis and preventing the accumulation of disease-associated proteins (Aguado2010Laforin).

Laforin interacts with malin, an E3 ubiquitin ligase, forming a complex that ubiquitinates and degrades proteins involved in glycogen biosynthesis. This interaction is vital for regulating glycogen metabolism and preventing the accumulation of abnormal glycogen aggregates (ZafraPuerta2023Gene; brewer2019biochemical).

## Clinical Significance
Mutations in the EPM2A gene, which encodes the laforin protein, are primarily associated with Lafora disease (LD), a severe form of progressive myoclonus epilepsy. This autosomal recessive disorder is characterized by myoclonus, generalized seizures, cognitive decline, and the presence of Lafora bodies, which are dense polyglucosan inclusions found in neurons and other tissues (Lesca2010Novel; Ianzano2005Lafora). Mutations in EPM2A lead to a loss of laforin's phosphatase activity, disrupting glycogen metabolism and resulting in the pathological accumulation of insoluble glycogen-like polyglucosans (Parihar2018Lafora; Singh2009Lafora).

The EPM2A gene undergoes alternative splicing, producing different isoforms of laforin, with mutations affecting these isoforms' interactions and functionality. The cytoplasmic isoform A is particularly implicated in LD pathogenesis, as mutations specific to this isoform result in reduced phosphatase activity and contribute to disease development (Singh2009Lafora; Ianzano2004Loss). Genotype-phenotype correlations in LD are complex, with some mutations linked to specific clinical presentations, such as childhood-onset learning disorders (Singh2009Lafora). The genetic diversity and allelic heterogeneity of EPM2A mutations contribute to the clinical variability observed in LD patients (Lesca2010Novel).

## Interactions
The EPM2A gene encodes laforin, a protein that interacts with several other proteins, playing a crucial role in glycogen metabolism and cellular stress responses. Laforin forms a complex with malin, an E3 ubiquitin ligase encoded by the EPM2B gene. This complex is essential for the ubiquitination and subsequent degradation of proteins involved in glycogen metabolism, such as glycogen synthase and protein targeting to glycogen (PTG) (Singh2009Lafora; brewer2019biochemical). The laforin-malin complex also interacts with components of the PI3KC3 complex, including Beclin1, Vps34, and Vps15, promoting their polyubiquitination and influencing autophagosome formation (SanchezMartin2020Regulation).

Laforin interacts with other proteins like glycogen synthase kinase 3 (GSK3) and AMP-activated kinase (AMPK), affecting glycogen synthesis regulation (Nitschke2018Lafora). It also binds to HIRIP5, involved in iron homeostasis, and EPM2AIP1, though the function of the latter is not well understood (Singh2009Lafora). Additionally, laforin and malin regulate the endocytosis of the glutamate transporter GLT-1, impacting its retention at the plasma membrane (Perez‐Jimenez2020Endocytosis). These interactions are critical for maintaining cellular homeostasis and preventing the pathological accumulation of glycogen, as seen in Lafora disease.


## References


[1. (Lesca2010Novel) Gaetan Lesca, Nadia Boutry‐Kryza, Bertrand De Toffol, Mathieu Milh, Dominique Steschenko, Martine Lemesle‐Martin, Louis Maillard, Giovanni Foletti, Gabrielle Rudolf, Jørgen Erik Nielsen, Bjarke á Rogvi‐Hansen, Jesper Erdal, Josette Mancini, Christel Thauvin‐Robinet, Amel M’Rrabet, Dorothée Ville, Pierre Szepetowski, Emmanuel Raffo, Edouard Hirsch, Philippe Ryvlin, Alain Calender, and Pierre Genton. Novel mutations in epm2a and nhlrc1 widen the spectrum of lafora disease. Epilepsia, 51(9):1691–1698, September 2010. URL: http://dx.doi.org/10.1111/j.1528-1167.2010.02692.x, doi:10.1111/j.1528-1167.2010.02692.x. This article has 42 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/j.1528-1167.2010.02692.x)

[2. (Castanheira2011Recombinant) Pedro Castanheira, Susana Moreira, Margarida Casal, Miguel Gama, and Carlos Faro. Recombinant Laforin for Structural Studies. InTech, September 2011. URL: http://dx.doi.org/10.5772/19169, doi:10.5772/19169. This article has 0 citations.](https://doi.org/10.5772/19169)

[3. (Singh2009Lafora) Shweta Singh and Subramaniam Ganesh. Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of theepm2aandnhlrc1genes. Human Mutation, 30(5):715–723, May 2009. URL: http://dx.doi.org/10.1002/humu.20954, doi:10.1002/humu.20954. This article has 94 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.20954)

[4. (Aguado2010Laforin) Carmen Aguado, Sovan Sarkar, Viktor I. Korolchuk, Olga Criado, Santiago Vernia, Patricia Boya, Pascual Sanz, Santiago Rodríguez de Córdoba, Erwin Knecht, and David C. Rubinsztein. Laforin, the most common protein mutated in lafora disease, regulates autophagy. Human Molecular Genetics, 19(14):2867–2876, May 2010. URL: http://dx.doi.org/10.1093/hmg/ddq190, doi:10.1093/hmg/ddq190. This article has 158 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddq190)

[5. (Roach2012Glycogen) Peter J. Roach, Anna A. Depaoli-Roach, Thomas D. Hurley, and Vincent S. Tagliabracci. Glycogen and its metabolism: some new developments and old themes. Biochemical Journal, 441(3):763–787, January 2012. URL: http://dx.doi.org/10.1042/bj20111416, doi:10.1042/bj20111416. This article has 516 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj20111416)

[6. (Nitschke2018Lafora) Felix Nitschke, Saija J. Ahonen, Silvia Nitschke, Sharmistha Mitra, and Berge A. Minassian. Lafora disease — from pathogenesis to treatment strategies. Nature Reviews Neurology, 14(10):606–617, August 2018. URL: http://dx.doi.org/10.1038/s41582-018-0057-0, doi:10.1038/s41582-018-0057-0. This article has 112 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41582-018-0057-0)

[7. (Emanuelle2016Unique) Shane Emanuelle, M. Kathryn Brewer, David A. Meekins, and Matthew S. Gentry. Unique carbohydrate binding platforms employed by the glucan phosphatases. Cellular and Molecular Life Sciences, 73(14):2765–2778, May 2016. URL: http://dx.doi.org/10.1007/s00018-016-2249-3, doi:10.1007/s00018-016-2249-3. This article has 23 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00018-016-2249-3)

[8. (Wang2002A) Jianyong Wang, Jeanne A. Stuckey, Matthew J. Wishart, and Jack E. Dixon. A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen. Journal of Biological Chemistry, 277(4):2377–2380, January 2002. URL: http://dx.doi.org/10.1074/jbc.c100686200, doi:10.1074/jbc.c100686200. This article has 132 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.c100686200)

[9. (Worby2006Laforin) Carolyn A. Worby, Matthew S. Gentry, and Jack E. Dixon. Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates. Journal of Biological Chemistry, 281(41):30412–30418, October 2006. URL: http://dx.doi.org/10.1074/jbc.m606117200, doi:10.1074/jbc.m606117200. This article has 173 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m606117200)

[10. (Dukhande2011Laforin) Vikas V. Dukhande, Devin M. Rogers, Carlos Romá-Mateo, Jordi Donderis, Alberto Marina, Adam O. Taylor, Pascual Sanz, and Matthew S. Gentry. Laforin, a dual specificity phosphatase involved in lafora disease, is present mainly as monomeric form with full phosphatase activity. PLoS ONE, 6(8):e24040, August 2011. URL: http://dx.doi.org/10.1371/journal.pone.0024040, doi:10.1371/journal.pone.0024040. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0024040)

11. (brewer2019biochemical) Biochemical Approaches for the Diagnosis and Treatment of Lafora Disease. This article has 1 citations.

[12. (Ianzano2004Loss) Leonarda Ianzano, Edwin J. Young, Xiao C. Zhao, Elayne M. Chan, M. T. Rodriguez, Maria V. Torrado, Stephen W. Scherer, and Berge A. Minassian. Loss of function of the cytoplasmic isoform of the protein laforin (epm2a) causes lafora progressive myoclonus epilepsy. Human Mutation, 23(2):170–176, January 2004. URL: http://dx.doi.org/10.1002/humu.10306, doi:10.1002/humu.10306. This article has 30 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.10306)

[13. (SanchezMartin2020Regulation) Pablo Sanchez-Martin, Marcos Lahuerta, Rosa Viana, Erwin Knecht, and Pascual Sanz. Regulation of the autophagic pi3kc3 complex by laforin/malin e3-ubiquitin ligase, two proteins involved in lafora disease. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1867(2):118613, February 2020. URL: http://dx.doi.org/10.1016/j.bbamcr.2019.118613, doi:10.1016/j.bbamcr.2019.118613. This article has 18 citations.](https://doi.org/10.1016/j.bbamcr.2019.118613)

[14. (Perez‐Jimenez2020Endocytosis) Eva Perez‐Jimenez, Rosa Viana, Carmen Muñoz‐Ballester, Carlos Vendrell‐Tornero, Raquel Moll‐Diaz, Maria Adelaida Garcia‐Gimeno, and Pascual Sanz. Endocytosis of the glutamate transporter 1 is regulated by laforin and malin: implications in <scp>lafora</scp> disease. Glia, 69(5):1170–1183, December 2020. URL: http://dx.doi.org/10.1002/glia.23956, doi:10.1002/glia.23956. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/glia.23956)

[15. (SánchezMartín2013Dimerization) Pablo Sánchez-Martín, Madushi Raththagala, Travis M. Bridges, Satrio Husodo, Matthew S. Gentry, Pascual Sanz, and Carlos Romá-Mateo. Dimerization of the glucan phosphatase laforin requires the participation of cysteine 329. PLoS ONE, 8(7):e69523, July 2013. URL: http://dx.doi.org/10.1371/journal.pone.0069523, doi:10.1371/journal.pone.0069523. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0069523)

[16. (Parihar2018Lafora) Rashmi Parihar, Anupama Rai, and Subramaniam Ganesh. Lafora disease: from genotype to phenotype. Journal of Genetics, 97(3):611–624, July 2018. URL: http://dx.doi.org/10.1007/s12041-018-0949-1, doi:10.1007/s12041-018-0949-1. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12041-018-0949-1)

17. (ZafraPuerta2023Gene) Gene replacement therapy for Lafora disease in theEpm2a-/-mouse model. This article has 1 citations.

[18. (Ianzano2005Lafora) Leonarda Ianzano, Junjun Zhang, Elayne M. Chan, Xiao-Chu Zhao, Hannes Lohi, Stephen W. Scherer, and Berge A. Minassian. Lafora progressive myoclonus epilepsy mutation database-epm2a and nhlrc1 (emp2b) genes. Human Mutation, 26(4):397–397, 2005. URL: http://dx.doi.org/10.1002/humu.9376, doi:10.1002/humu.9376. This article has 46 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.9376)